• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫颈鳞状细胞癌、腺癌和腺鳞癌女性患者的生存率真的存在差异吗?

Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?

作者信息

Shingleton H M, Bell M C, Fremgen A, Chmiel J S, Russell A H, Jones W B, Winchester D P, Clive R E

机构信息

Emory University, Atlanta, Georgia, USA.

出版信息

Cancer. 1995 Nov 15;76(10 Suppl):1948-55. doi: 10.1002/1097-0142(19951115)76:10+<1948::aid-cncr2820761311>3.0.co;2-t.

DOI:10.1002/1097-0142(19951115)76:10+<1948::aid-cncr2820761311>3.0.co;2-t
PMID:8634986
Abstract

BACKGROUND

The authors' aim was to assess whether there is a difference in biologic behavior and survival in comparing adenocarcinoma (AdCA), squamous cell carcinoma (SCC), and adenosquamous carcinoma (Ad/SC) of the cervix.

METHODS

Cancer registrars at 703 hospitals submitted anonymous data on 11,157 patients with cervical cancer diagnosed and/or treated in 1984 and 1990 for a Patient Care Evaluation Study of the American College of Surgeons. Among these patients, 9351 (83.8%) had SCC; 1405 (12.6%), AdCA; and 401 (3.6%), Ad/SC cancers. There were no significant changes in percentages of the different histologic types between the study years 1984 and 1990, nor was the patient distribution different regarding age, race/ethnicity, and socioeconomic background for each histologic group. Furthermore, the distribution of patients who had had a hysterectomy did not change between 1984 and 1990.

RESULTS

A larger percent of patients with SCC (63.8%) than those with Ad/SC (59.8%) or AdCA (50.2%) had tumors larger than 3 cm at greatest dimension. Early stage patients (IA, IB, IIA) often were treated by hysterectomy alone (45.5%) or combined with radiation (21.1%). The remaining patients (21.9%) received radiation alone. Of the patients with clinical stage I disease, 7.6% of Ad/CA patients, 15.5% of Ad/SC patients and 12.6% of SCC patients had positive nodes. Although patients with SCC had higher survival rates for all four clinical stages (I-IV), the differences were only significant for Stage II patients. Patients with clinical stage IB SCC and AdCA treated by surgery alone were found to have significantly better survival rates (93.1% and 94.6% at 5 years, respectively) than women treated by either radiation alone or a combination of surgery and radiation (P < 0.001, both histologic comparisons). For women with Ad/SC tumors, however, the 5-year survival rate was 87.3% for those receiving combined treatment compared with those receiving surgery alone (69.2%) or radiation alone (79.2%). However, these survival curves were not significantly different (P = 0.496). One hundred six patients with positive nodes were available for analysis. The 5-year survival rate of patients with SCC and positive nodes was 76.1%. Surprisingly, patients with Ad/SC and positive nodes had the highest 5-year survival rate (85.7%), whereas, women with AdCA and positive nodes had a sharply reduced 5-year survival rate (33.3%). The curves were significantly different (P < 0.01). For patients with clinical stage I, the risk factors for age, tumor size, nodal status, histologic features, and treatment were analyzed with Cox's multivariate regression. In this analysis, subset IB, greater tumor size, age 80 or older, and positive nodal status were each independently significant for poorer survival. Patients who were treated by surgery alone had a significantly better survival than patients who had other types of treatment or no treatment. Histologic characteristics had no significant effect on survival. In the analysis of patients with pathologic stage I disease, those with SCC had significantly poorer survival and those with Ad/SC had significantly better survival than patients with Ad/CA. Positive nodes had no significant independent effect on survival. In another analysis, tissue type was not found to be an important factor in recurrence time.

CONCLUSIONS

  1. Ad/CA and Ad/SC tumors were found to represent 12.6% and 3.6%, respectively, of a large series (N = 11,157) of cervical cancers diagnosed in 1984 and 1990 and reported to the Commission on Cancer of the American College of Surgeons. 2. Two thirds of women with early clinical stage disease (IA, IB, IIA) had hysterectomy as all or part of their primary therapy. 3. No significant differences were found in 5-year survival among the three tissue types in any clinical stage except American Joint Committee on Cancer stage II.
摘要

背景

作者的目的是评估子宫颈腺癌(AdCA)、鳞状细胞癌(SCC)和腺鳞癌(Ad/SC)在生物学行为和生存率方面是否存在差异。

方法

703家医院的癌症登记员提交了1984年和1990年诊断和/或治疗的11157例宫颈癌患者的匿名数据,用于美国外科医师学会的患者护理评估研究。在这些患者中,9351例(83.8%)为SCC;1405例(12.6%)为AdCA;401例(3.6%)为Ad/SC癌。在1984年和1990年的研究年份之间,不同组织学类型的百分比没有显著变化,并且每个组织学组在年龄、种族/民族和社会经济背景方面的患者分布也没有差异。此外,1984年至1990年间接受子宫切除术的患者分布没有变化。

结果

SCC患者中肿瘤最大直径大于3cm的比例(63.8%)高于Ad/SC患者(59.8%)或AdCA患者(50.2%)。早期患者(IA、IB、IIA期)通常仅接受子宫切除术(45.5%)或联合放疗(21.1%)。其余患者(21.9%)仅接受放疗。在临床I期患者中,Ad/CA患者的7.6%、Ad/SC患者的15.5%和SCC患者的12.6%有阳性淋巴结。尽管SCC患者在所有四个临床分期(I-IV期)的生存率较高,但差异仅在II期患者中显著。发现单独接受手术治疗的临床IB期SCC和AdCA患者的生存率(5年时分别为93.1%和94.6%)明显高于单独接受放疗或手术与放疗联合治疗的女性(P<0.001,两种组织学比较均如此)。然而,对于患有Ad/SC肿瘤的女性,接受联合治疗的患者5年生存率为87.3%,而接受单独手术(69.2%)或单独放疗(79.2%)的患者生存率较低。然而,这些生存曲线没有显著差异(P = 0.496)。106例有阳性淋巴结的患者可供分析。SCC且有阳性淋巴结患者的5年生存率为76.1%。令人惊讶的是,Ad/SC且有阳性淋巴结患者的5年生存率最高(85.7%),而AdCA且有阳性淋巴结的女性5年生存率急剧下降(33.3%)。曲线有显著差异(P<0.01)。对于临床I期患者,使用Cox多变量回归分析年龄、肿瘤大小、淋巴结状态、组织学特征和治疗的危险因素。在此分析中,子集IB、更大的肿瘤大小、80岁或以上的年龄以及阳性淋巴结状态各自独立地对较差的生存有显著影响。单独接受手术治疗的患者生存率明显高于接受其他类型治疗或未接受治疗的患者。组织学特征对生存没有显著影响。在病理I期疾病患者的分析中,SCC患者的生存率明显较差,Ad/SC患者的生存率明显高于Ad/CA患者。阳性淋巴结对生存没有显著的独立影响。在另一项分析中,未发现组织类型是复发时间的重要因素。

结论

  1. 在1984年和1990年诊断并报告给美国外科医师学会癌症委员会的一大系列(N = 11157)宫颈癌中,Ad/CA和Ad/SC肿瘤分别占12.6%和3.6%。2. 三分之二的早期临床疾病(IA、IB、IIA期)女性将子宫切除术作为其主要治疗的全部或部分。3. 除美国癌症联合委员会II期外,在任何临床分期中,三种组织学类型的5年生存率均未发现显著差异。

相似文献

1
Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?子宫颈鳞状细胞癌、腺癌和腺鳞癌女性患者的生存率真的存在差异吗?
Cancer. 1995 Nov 15;76(10 Suppl):1948-55. doi: 10.1002/1097-0142(19951115)76:10+<1948::aid-cncr2820761311>3.0.co;2-t.
2
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.
3
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.腺鳞组织学特征预示晚期宫颈癌患者预后不良,但早期宫颈癌患者并非如此。
Cancer. 2003 May 1;97(9):2196-202. doi: 10.1002/cncr.11371.
4
Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-stage carcinoma of the uterine cervix.高危早期宫颈癌根治性手术后同步放化疗后巩固化疗的初步结果
Clin Oncol (R Coll Radiol). 2005 Sep;17(6):412-7. doi: 10.1016/j.clon.2005.02.006.
5
Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy.宫颈腺鳞癌:早期疾病行根治性子宫切除术后的预后
Gynecol Oncol. 1993 Sep;50(3):310-5. doi: 10.1006/gyno.1993.1217.
6
Impact of histology on prognosis of patients with early-stage cervical cancer treated with radical surgery.组织学对接受根治性手术治疗的早期宫颈癌患者预后的影响。
Int J Gynaecol Obstet. 2011 Nov;115(2):183-7. doi: 10.1016/j.ijgo.2011.06.011. Epub 2011 Aug 31.
7
Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.比较 FIGO 分期 IB-IIA 期宫颈癌根治术后中国患者腺癌和腺鳞癌的预后。
BMC Cancer. 2020 Jul 16;20(1):664. doi: 10.1186/s12885-020-07148-x.
8
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.一项关于手术分期为IB期宫颈癌患者细胞类型的分析:妇科肿瘤学组研究
Gynecol Oncol. 1996 Dec;63(3):304-11. doi: 10.1006/gyno.1996.0327.
9
A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix.子宫颈病理I b期腺癌与鳞状细胞癌预后的比较。
Gynecol Oncol. 2000 Nov;79(2):289-93. doi: 10.1006/gyno.2000.5935.
10
Prognosis and treatment of primary adenocarcinoma and adenosquamous cell carcinoma of the uterine cervix.子宫颈原发性腺癌和腺鳞癌的预后与治疗
Eur J Gynaecol Oncol. 2001;22(2):160-3.

引用本文的文献

1
The Role of Pelvic Exenteration in Cervical Cancer: A Review of the Literature.盆腔脏器切除术在宫颈癌中的作用:文献综述
Cancers (Basel). 2024 Feb 18;16(4):817. doi: 10.3390/cancers16040817.
2
Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma.宫颈鳞癌和腺癌的免疫景观和异质性。
Aging (Albany NY). 2024 Jan 10;16(1):568-592. doi: 10.18632/aging.205397.
3
Prognostic Factors of Cervical Adenocarcinoma With Positive Pelvic Lymph Node Metastases Without Preoperative Lymph Node Enlargement Treated With Radical Hysterectomy.
根治性子宫切除术治疗术前未出现淋巴结肿大但盆腔淋巴结转移阳性的宫颈腺癌的预后因素
Cancer Diagn Progn. 2023 Jan 3;3(1):96-101. doi: 10.21873/cdp.10185. eCollection 2023 Jan-Feb.
4
The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma.早期宫颈腺鳞癌患者的最佳术后辅助治疗。
BMC Womens Health. 2022 Apr 12;22(1):112. doi: 10.1186/s12905-021-01588-8.
5
Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management.子宫颈腺鳞癌——组织学对临床管理的影响
Cancer Manag Res. 2021 Jun 23;13:4979-4986. doi: 10.2147/CMAR.S311326. eCollection 2021.
6
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.HER3蛋白表达作为早期宫颈癌腺癌和腺鳞癌患者术后复发的危险因素。
Oncol Lett. 2020 Oct;20(4):38. doi: 10.3892/ol.2020.11899. Epub 2020 Jul 23.
7
Neoadjuvant intra-arterial chemotherapy using an original four-lumen double-balloon catheter for locally advanced uterine cervical cancer.使用原创四腔双球囊导管对局部晚期子宫颈癌进行新辅助动脉内化疗。
Oncotarget. 2018 Dec 28;9(102):37766-37776. doi: 10.18632/oncotarget.26518.
8
Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates.新辅助治疗宫颈癌腺癌和鳞癌的病理完全缓解率有显著差异。
BMC Cancer. 2018 Nov 12;18(1):1101. doi: 10.1186/s12885-018-5007-0.
9
A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.IB-IIA 期宫颈癌中腺癌与鳞癌预后的比较。
Int J Clin Oncol. 2018 Jun;23(3):522-531. doi: 10.1007/s10147-017-1225-8. Epub 2018 Jan 3.
10
Prediction of 5-year overall survival in cervical cancer patients treated with radical hysterectomy using computational intelligence methods.使用计算智能方法预测接受根治性子宫切除术的宫颈癌患者的5年总生存率。
BMC Cancer. 2017 Dec 12;17(1):840. doi: 10.1186/s12885-017-3806-3.